Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alto Neuroscience, Inc. (ANRO)
USD26.67
-1.13 (-4.06%)
US NYSE Healthcare Biotechnology
Address
369 South San Antonio Road 94022
Mountain View, CA, US
Mountain View, CA, US
CEO
Amit Etkin
Website
altoneuroscience.com
IPO
2024-02-02
CIK 1999480 ISIN US02157Q1094
Description
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD26.67
-1.13 (-4.06%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
407.7K
Beta
1.25
Float Shares
28.72M
Free Float %
89.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.23% | -6.62% | -11.26% | +35.29% | +101.32% | +28.37% | +864.14% | +10.39% | +10.39% | +10.39% | +10.39% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
26.67
Low
28.00
+5.0%
Consensus
31.50
+18.1%
Median
31.50
+18.1%
High
35.00
+31.2%
DCF (Unlevered)
5.91
-77.9%
DCF (Levered)
5.96
-77.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
91% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 10 | +1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
31.50
+18.1%
|
| Last Year | 3 |
26.33
-1.3%
|
| All Time | 5 |
24.20
-9.3%
|
Quality scores
Altman Z-Score
13.42
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+12.4% Q1'26: -42.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+17.3% Q1'26: +21.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.07× Q1'26: -0.05× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 EPS Ana. |
Dec 2027 5 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
—
— – —
|
9.30M
9.30M – 9.30M
|
46.69M
46.69M – 46.69M
+402.1% YoY
|
281.25M
281.25M – 281.25M
+502.4% YoY
|
| EBITDA |
-68.61M
|
-65.70M
|
—
— – —
|
—
— – —
|
5.58M
5.58M – 5.58M
|
28.01M
28.01M – 28.01M
+402.1% YoY
|
168.75M
168.75M – 168.75M
+502.4% YoY
|
| EBIT |
-62.81M
|
-66.36M
|
—
— – —
|
—
— – —
|
5.58M
5.58M – 5.58M
|
28.01M
28.01M – 28.01M
+402.1% YoY
|
168.75M
168.75M – 168.75M
+502.4% YoY
|
| Net Income |
-61.43M
est: -63.18M (+2.8%)
|
-63.24M
est: -63.24M (+0.0%)
|
-89.27M
-114.72M – -50.02M
-41.2% YoY
|
-121.15M
-122.94M – -56.24M
-35.7% YoY
|
-90.31M
-118.58M – -62.03M
+25.5% YoY
|
-70.54M
-70.54M – -70.54M
+21.9% YoY
|
24.58M
24.58M – 24.58M
+134.8% YoY
|
| SGA |
21.61M
|
20.75M
|
—
— – —
|
—
— – —
|
40.66M
40.66M – 40.66M
|
204.15M
204.15M – 204.15M
+402.1% YoY
|
1.23B
1.23B – 1.23B
+502.4% YoY
|
| EPS |
-2.50
est: -2.59 (+3.3%)
|
-2.19
est: -2.24 (+2.2%)
|
-2.42
-3.98 – -1.73
-8.0% YoY
|
-2.93
-4.26 – -1.95
-21.0% YoY
|
-2.88
-4.11 – -2.15
+1.8% YoY
|
-2.45
-2.45 – -2.45
+15.0% YoY
|
0.85
0.85 – 0.85
+134.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-11 | HC Wainwright & Co. | Buy | Buy | Maintain |
| 2026-04-22 | Chardan Capital | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-62.30M
OE per share TTM
-2.06
Owner's Yield
-8.29%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
8,371.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
23
Total invested
44.41M
Insider transactions (90d)
0
Beneficial owners (>5%)
18
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Alpha Wave Global, LP | 3.71M | 13.80% | — | 3.71M | — | — | IA | Delaware | 2024-02-09 | ↗ |
| 2 | Alpha Wave Ventures GP, Ltd | 3.71M | 13.80% | — | 3.71M | — | — | OO | Cayman Islands | 2024-02-09 | ↗ |
| 3 | Chimera Investment LLC | 3.71M | 13.80% | — | 3.71M | — | — | OO | United Arab Emirates | 2024-02-09 | ↗ |
| 4 | Lunate Holding RSC LTD | 3.71M | 13.80% | — | 3.71M | — | — | OO | United Arab Emirates | 2024-02-09 | ↗ |
| 5 | Abigail P. Johnson | 2.36M | 8.77% | — | — | 2.36M | — | IN | Delaware | 2024-11-12 | ↗ |
| 6 | FMR LLC | 2.36M | 8.77% | 2.36M | — | 2.36M | — | HC | Delaware | 2024-11-12 | ↗ |
| 7 | Steven A. Cohen | 1.69M | 6.30% | — | 1.69M | — | — | IN | United States | 2024-02-07 | ↗ |
| 8 | Amit Etkin | 1.46M | 5.40% | 1.46M | — | 1.46M | — | IN | — | 2024-11-14 | ↗ |
| 9 | (1) BlackRock, Inc. | 1.45M | 5.40% | 1.43M | — | 1.45M | — | HC | Delaware | 2024-11-08 | ↗ |
| 10 | Peter Kolchinsky | 1.39M | 5.20% | — | 1.39M | — | — | HC, IN | Delaware | 2024-03-29 | ↗ |
| 11 | RA Capital Healthcare Fund, L.P. | 1.39M | 5.20% | — | 1.39M | — | — | PN | Delaware | 2024-03-29 | ↗ |
| 12 | RA Capital Management, L.P. | 1.39M | 5.20% | — | 1.39M | — | — | IA, PN | Delaware | 2024-03-29 | ↗ |
| 13 | Rajeev Shah | 1.39M | 5.20% | — | 1.39M | — | — | HC, IN | Delaware | 2024-03-29 | ↗ |
| 14 | Point72 Asset Management, L.P. | 1.03M | 3.80% | — | 1.03M | — | — | PN | Delaware | 2024-02-07 | ↗ |
| 15 | Point72 Capital Advisors, Inc. | 1.03M | 3.80% | — | 1.03M | — | — | CO | Delaware | 2024-02-07 | ↗ |
| 16 | 72 Investment Holdings, LLC | 667.8K | 2.50% | — | 667.8K | — | — | OO | Delaware | 2024-02-07 | ↗ |
| 17 | Differentiated Ventures Investments, LLC | 667.8K | 2.50% | — | 667.8K | — | — | OO | Delaware | 2024-02-07 | ↗ |
| 18 | Point72 Biotech Private Investments, LLC | 667.8K | 2.50% | — | 667.8K | — | — | OO | Delaware | 2024-02-07 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
23
-78 vs prev Q
New positions
7
Closed positions
82
Increased
8
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 222.8K +222.8K (+100.0%) | 3.97B +4.0B (+100.0%) | 0.82% +0.822 pp | 1.31% +1.311 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 2 | ALPHA WAVE GLOBAL, LP | 3.71M +— (+0.0%) | 66.00M +51.1M (+342.8%) | 13.68% -0.016 pp | 8.09% +6.581 pp | USD14.56 +22.3% | 8 qtrs — |
| 3 | VESTAL POINT CAPITAL, LP | 2.49M +1.5M (+161.6%) | 44.23M +40.4M (+1,058.2%) | 9.17% +5.659 pp | 1.50% +1.331 pp | USD14.78 +20.4% | 8 qtrs — |
| 4 | COMMODORE CAPITAL LP | 1.82M +1.8M (+100.0%) | 32.45M +32.5M (+100.0%) | 6.73% +6.727 pp | 2.16% +2.160 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 5 | PERCEPTIVE ADVISORS LLC | 1.78M +1.6M (+1,048.5%) | 31.76M +31.1M (+4,985.4%) | 6.58% +6.010 pp | 0.57% +0.548 pp | USD16.60 +7.2% | 2 qtrs — |
| 6 | POINT72 ASSET MANAGEMENT, L.P. | 1.61M +274.5K (+20.6%) | 28.60M +23.2M (+434.0%) | 5.93% +1.007 pp | 0.03% +0.023 pp | USD11.04 +61.2% | 8 qtrs — |
| 7 | ARMISTICE CAPITAL, LLC | 1.54M -100.0K (-6.1%) | 27.34M +20.8M (+315.7%) | 5.67% -0.376 pp | 0.33% +0.228 pp | USD3.00 +493.3% | 5 qtrs — |
| 8 | VANGUARD GROUP INC | 1.37M +260.4K (+23.6%) | 24.31M +19.9M (+447.1%) | 5.04% +0.956 pp | 0.00% +0.000 pp | USD13.58 +31.1% | 8 qtrs — |
| 9 | FRANKLIN RESOURCES INC | 1.12M -43.0K (-3.7%) | 19.93M +15.3M (+326.4%) | 4.13% -0.164 pp | 0.00% +0.004 pp | USD13.04 +36.5% | 8 qtrs — |
| 10 | VIVO CAPITAL, LLC | 1.04M +1.0M (+100.0%) | 18.43M +18.4M (+100.0%) | 3.82% +3.821 pp | 1.19% +1.192 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 11 | 72 INVESTMENT HOLDINGS, LLC | 667.8K +— (+0.0%) | 11.89M +9.2M (+342.8%) | 2.46% -0.003 pp | 23.50% +19.552 pp | USD14.56 +22.3% | 8 qtrs — |
| 12 | MILLENNIUM MANAGEMENT LLC | 630.0K +314.2K (+99.5%) | 11.21M +9.9M (+783.4%) | 2.32% +1.158 pp | 0.00% +0.004 pp | USD10.02 +77.6% | 4 qtrs — |
| 13 | BLACKROCK, INC. | 607.9K +240.0K (+65.2%) | 10.82M +9.3M (+631.6%) | 2.24% +0.884 pp | 0.00% +0.000 pp | USD13.85 +28.5% | 6 qtrs — |
| 14 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 212.7K +211.2K (+14,567.0%) | 10.73M +10.7M (+183,967.7%) | 0.78% +0.779 pp | 0.01% +0.007 pp | USD17.71 +0.5% | 2 qtrs — |
| 15 | IKARIAN CAPITAL, LLC | 515.0K +405.0K (+368.2%) | 9.17M +8.7M (+1,973.0%) | 1.90% +1.494 pp | 0.72% +0.671 pp | USD14.90 +19.5% | 5 qtrs — |
| 16 | ALKEON CAPITAL MANAGEMENT LLC | 477.1K +— (+0.0%) | 8.49M +6.6M (+342.8%) | 1.76% -0.002 pp | 0.01% +0.011 pp | USD11.40 +56.1% | 7 qtrs — |
| 17 | NORTHERN TRUST CORP | 474.4K +13.1K (+2.8%) | 8.44M +6.6M (+355.3%) | 1.75% +0.046 pp | 0.00% +0.001 pp | USD7.02 +153.6% | 8 qtrs — |
| 18 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 375.0K -25.0K (-6.3%) | 6.68M +5.1M (+315.1%) | 1.38% -0.094 pp | 0.33% +0.223 pp | USD3.71 +379.8% | 5 qtrs — |
| 19 | DRIEHAUS CAPITAL MANAGEMENT LLC | 336.8K +336.8K (+100.0%) | 5.99M +6.0M (+100.0%) | 1.24% +1.243 pp | 0.04% +0.041 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 20 | GEODE CAPITAL MANAGEMENT, LLC | 287.4K +49.5K (+20.8%) | 5.12M +4.2M (+434.9%) | 1.06% +0.182 pp | 0.00% +0.000 pp | USD12.51 +42.3% | 8 qtrs — |
| 21 | PEAPOD LANE CAPITAL LLC | 254.0K -28.0K (-9.9%) | 4.52M +3.4M (+297.9%) | 0.94% -0.104 pp | 3.85% +2.830 pp | USD2.22 +701.8% | 3 qtrs — |
| 22 | AWM INVESTMENT COMPANY, INC. | 225.0K -55.5K (-19.8%) | 4.01M +2.9M (+255.2%) | 0.83% -0.206 pp | 0.39% +0.281 pp | USD9.25 +92.4% | 8 qtrs — |
| 23 | MARSHALL WACE, LLP | 193.1K -632.1K (-76.6%) | 3.44M +119.9K (+3.6%) | 0.71% -2.336 pp | 0.00% 0.000 pp | USD4.01 +343.9% | 5 qtrs — |
| 24 | TWO SIGMA ADVISERS, LP | 160.1K +10.2K (+6.8%) | 2.85M +2.2M (+372.9%) | 0.59% +0.037 pp | 0.01% +0.004 pp | USD3.96 +349.5% | 4 qtrs — |
| 25 | GOLDMAN SACHS GROUP INC | 156.3K +66.1K (+73.2%) | 2.78M +2.4M (+666.9%) | 0.58% +0.243 pp | 0.00% +0.000 pp | USD10.53 +69.0% | 7 qtrs — |
| 26 | TWO SIGMA INVESTMENTS, LP | 140.3K +23.7K (+20.4%) | 2.50M +2.0M (+432.9%) | 0.52% +0.087 pp | 0.00% +0.003 pp | USD6.72 +164.9% | 6 qtrs — |
| 27 | BOOTHBAY FUND MANAGEMENT, LLC | 139.3K +106.8K (+329.0%) | 2.48M +2.3M (+1,799.5%) | 0.51% +0.394 pp | 0.04% +0.035 pp | USD14.64 +21.6% | 5 qtrs — |
| 28 | STATE STREET CORP | 130.7K +27.5K (+26.6%) | 2.33M +1.9M (+460.7%) | 0.48% +0.101 pp | 0.00% +0.000 pp | USD11.23 +58.5% | 8 qtrs — |
| 29 | ORBIMED ADVISORS LLC | 125.0K -125.0K (-50.0%) | 2.23M +1.2M (+121.4%) | 0.46% -0.462 pp | 0.05% +0.022 pp | USD4.23 +320.8% | 5 qtrs — |
| 30 | D. E. SHAW & CO., INC. | 124.8K +124.8K (+100.0%) | 2.22M +2.2M (+100.0%) | 0.46% +0.460 pp | 0.00% +0.001 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 31 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 118.2K -37.5K (-24.1%) | 2.10M +1.5M (+236.1%) | 0.44% -0.139 pp | 0.00% +0.000 pp | USD3.67 +385.0% | 5 qtrs — |
| 32 | QUBE RESEARCH & TECHNOLOGIES LTD | 112.8K +112.8K (+100.0%) | 2.01M +2.0M (+100.0%) | 0.42% +0.416 pp | 0.00% +0.002 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 33 | RENAISSANCE TECHNOLOGIES LLC | 97.4K +21.6K (+28.5%) | 1.73M +1.4M (+469.2%) | 0.36% +0.080 pp | 0.00% +0.002 pp | USD6.43 +176.8% | 3 qtrs — |
| 34 | STIFEL FINANCIAL CORP | 87.2K -34.8K (-28.6%) | 1.55M +1.1M (+216.3%) | 0.32% -0.129 pp | 0.00% +0.001 pp | USD4.21 +322.8% | 5 qtrs — |
| 35 | ALMITAS CAPITAL LLC | 78.5K -116.6K (-59.8%) | 1.40M +613.2K (+78.2%) | 0.29% -0.431 pp | 0.31% +0.128 pp | USD4.23 +320.8% | 5 qtrs — |
| 36 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 77.7K +— (+0.0%) | 1.38M +1.1M (+342.8%) | 0.29% 0.000 pp | 0.03% +0.022 pp | USD2.74 +549.6% | 4 qtrs — |
| 37 | IEQ CAPITAL, LLC | 75.3K +12.3K (+19.6%) | 1.34M +1.1M (+429.4%) | 0.28% +0.045 pp | 0.00% +0.003 pp | USD12.48 +42.6% | 6 qtrs — |
| 38 | WELLINGTON MANAGEMENT GROUP LLP | 69.0K +69.0K (+100.0%) | 1.23M +1.2M (+100.0%) | 0.25% +0.255 pp | 0.00% +0.000 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 39 | MORGAN STANLEY | 65.6K +4.5K (+7.4%) | 1.17M +922.0K (+375.8%) | 0.24% +0.017 pp | 0.00% +0.000 pp | USD6.61 +169.3% | 8 qtrs — |
| 40 | 683 CAPITAL MANAGEMENT, LLC | 64.8K +64.8K (+100.0%) | 1.15M +1.2M (+100.0%) | 0.24% +0.239 pp | 0.05% +0.050 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 41 | ACADIAN ASSET MANAGEMENT LLC | 57.5K +43.0K (+296.2%) | 1.02M +962.0K (+1,658.6%) | 0.21% +0.159 pp | 0.00% +0.002 pp | USD13.86 +28.4% | 3 qtrs — |
| 42 | JANE STREET GROUP, LLC | 47.7K +47.7K (+100.0%) | 849.1K +849.1K (+100.0%) | 0.18% +0.176 pp | 0.00% +0.000 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 43 | ADVISORSHARES INVESTMENTS LLC | 44.1K +44.1K (+100.0%) | 784.6K +784.6K (+100.0%) | 0.16% +0.163 pp | 0.13% +0.131 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 44 | ALLIANZ ASSET MANAGEMENT GMBH | 43.0K +6.0K (+16.2%) | 765.4K +616.7K (+414.6%) | 0.16% +0.022 pp | 0.00% +0.001 pp | USD9.81 +81.4% | 6 qtrs — |
| 45 | QUANTINNO CAPITAL MANAGEMENT LP | 35.6K +— (+0.0%) | 633.3K +490.3K (+342.8%) | 0.13% 0.000 pp | 0.00% +0.001 pp | USD2.20 +709.1% | 3 qtrs — |
| 46 | HUDSON BAY CAPITAL MANAGEMENT LP | 34.8K +34.8K (+100.0%) | 619.2K +619.2K (+100.0%) | 0.13% +0.128 pp | 0.00% +0.002 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 47 | SCS CAPITAL MANAGEMENT LLC | 33.4K -33.4K (-50.0%) | 594.3K +325.9K (+121.4%) | 0.12% -0.124 pp | 0.01% +0.003 pp | USD2.16 +724.1% | 4 qtrs — |
| 48 | BNP PARIBAS ARBITRAGE, SNC | 33.2K +32.7K (+6,366.0%) | 591.6K +589.5K (+28,534.2%) | 0.12% +0.121 pp | 0.00% +0.000 pp | USD17.60 +1.1% | 7 qtrs — |
| 49 | DIMENSIONAL FUND ADVISORS LP | 31.2K +31.2K (+100.0%) | 554.9K +554.9K (+100.0%) | 0.12% +0.115 pp | 0.00% +0.000 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 50 | BARCLAYS PLC | 30.4K +793.0 (+2.7%) | 541.0K +202.4K (+59.8%) | 0.11% +0.003 pp | 0.00% +0.000 pp | USD4.38 +306.4% | 8 qtrs — |
| 51 | PRICE T ROWE ASSOCIATES INC /MD/ | 30.2K -29.2K (-49.1%) | 539.0K +300.0K (+125.5%) | 0.11% -0.108 pp | 0.00% +0.000 pp | USD12.44 +43.1% | 8 qtrs — |
| 52 | ARTIA GLOBAL PARTNERS LP | 29.2K +29.2K (+100.0%) | 519.6K +519.6K (+100.0%) | 0.11% +0.108 pp | 0.08% +0.083 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 53 | CITIZENS FINANCIAL GROUP INC/RI | 28.2K -11.8K (-29.5%) | 501.8K +341.0K (+212.1%) | 0.10% -0.044 pp | 0.01% +0.005 pp | USD2.46 +623.6% | 4 qtrs — |
| 54 | ALPS ADVISORS INC | 25.5K +25.5K (+100.0%) | 454.0K +454.0K (+100.0%) | 0.09% +0.094 pp | 0.00% +0.003 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 55 | BROWN ADVISORY INC | 25.0K +— (+0.0%) | 445.0K +344.5K (+342.8%) | 0.09% 0.000 pp | 0.00% +0.001 pp | USD4.23 +320.8% | 5 qtrs — |
| 56 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO | 22.2K +— (+0.0%) | 394.7K +305.6K (+342.8%) | 0.08% 0.000 pp | 0.06% +0.043 pp | USD14.56 +22.3% | 8 qtrs — |
| 57 | XTX TOPCO LTD | 20.8K +5.1K (+32.2%) | 370.7K +307.4K (+485.6%) | 0.08% +0.019 pp | 0.01% +0.006 pp | USD7.38 +141.2% | 2 qtrs — |
| 58 | ALPHACORE CAPITAL LLC | 20.0K +10.0K (+100.0%) | 356.0K +315.8K (+785.6%) | 0.07% +0.037 pp | 0.01% +0.007 pp | USD9.99 +78.2% | 4 qtrs — |
| 59 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 18.8K +18.8K (+100.0%) | 334.4K +334.4K (+100.0%) | 0.07% +0.069 pp | 0.00% +0.003 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 60 | UBS GROUP AG | 18.5K -120.5K (-86.7%) | 329.1K -229.8K (-41.1%) | 0.07% -0.445 pp | 0.00% +0.000 pp | USD4.29 +314.9% | 8 qtrs — |
| 61 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 17.1K +17.1K (+100.0%) | 303.7K +303.7K (+100.0%) | 0.06% +0.063 pp | 0.00% +0.000 pp | USD17.80 +0.0% | 8 qtrs — |
| 62 | CITADEL ADVISORS LLC | 16.8K +16.8K (+100.0%) | 299.0K +299.0K (+100.0%) | 0.06% +0.062 pp | 0.00% +0.000 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 63 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 16.5K -560.0 (-3.3%) | 293.4K +224.9K (+328.2%) | 0.06% -0.002 pp | 0.00% +0.002 pp | USD2.42 +635.5% | 3 qtrs — |
| 64 | AMERIPRISE FINANCIAL INC | 13.5K +— (+0.0%) | 240.1K +185.9K (+342.8%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD10.99 +62.0% | 6 qtrs — |
| 65 | CITIGROUP INC | 12.6K +12.6K (+100.0%) | 223.7K +223.7K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.000 pp | USD17.80 +0.0% | 8 qtrs — |
| 66 | OMERS ADMINISTRATION CORP | 12.4K +12.4K (+100.0%) | 220.7K +220.7K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.002 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 67 | BANK OF MONTREAL /CAN/ | 11.4K +13.0 (+0.1%) | 202.1K +156.5K (+343.3%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD2.22 +701.8% | 3 qtrs — |
| 68 | BALYASNY ASSET MANAGEMENT L.P. | 11.1K +11.1K (+100.0%) | 197.9K +197.9K (+100.0%) | 0.04% +0.041 pp | 0.00% +0.000 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 69 | BANK OF AMERICA CORP /DE/ | 11.1K +11.0K (+8,845.2%) | 197.4K +196.9K (+39,546.0%) | 0.04% +0.041 pp | 0.00% +0.000 pp | USD17.70 +0.6% | 8 qtrs — |
| 70 | AMERICAN CENTURY COMPANIES INC | 10.4K +10.4K (+100.0%) | 184.4K +184.4K (+100.0%) | 0.04% +0.038 pp | 0.00% +0.000 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 71 | FMR LLC | 6.4K -1.3K (-17.0%) | 113.5K +82.6K (+267.7%) | 0.02% -0.005 pp | 0.00% +0.000 pp | USD14.45 +23.2% | 8 qtrs — |
| 72 | QUEST PARTNERS LLC | 3.8K +3.8K (+100.0%) | 68.0K +68.0K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.004 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 73 | ROTHSCHILD INVESTMENT LLC | 2.9K +— (+0.0%) | 51.4K +39.8K (+342.8%) | 0.01% +0.000 pp | 0.00% +0.002 pp | USD11.44 +55.6% | 6 qtrs — |
| 74 | WHITTIER TRUST CO OF NEVADA INC | 2.5K +— (+0.0%) | 37.4K +20.3K (+118.9%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD4.23 +320.8% | 5 qtrs — |
| 75 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.0K -403.0 (-16.9%) | 35.4K +25.8K (+268.1%) | 0.01% -0.002 pp | 0.00% +0.001 pp | USD5.56 +220.1% | 8 qtrs — |
| 76 | GROUP ONE TRADING, L.P. | 1.4K -1.2K (-46.8%) | 25.2K +14.5K (+135.4%) | 0.01% -0.005 pp | 0.00% +0.000 pp | USD3.45 +415.9% | 4 qtrs — |
| 77 | PNC FINANCIAL SERVICES GROUP, INC. | 1.3K -159.0 (-10.8%) | 23.3K +17.4K (+294.8%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD2.20 +709.1% | 4 qtrs — |
| 78 | SIGNATUREFD, LLC | 1.1K +1.1K (+100.0%) | 19.0K +19.0K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 79 | FEDERATED HERMES, INC. | 770.00 -2.6K (-77.0%) | 13.7K +251.0 (+1.9%) | 0.00% -0.010 pp | 0.00% +0.000 pp | USD3.60 +394.4% | 3 qtrs — |
| 80 | WELLS FARGO & COMPANY/MN | 765.00 +765.0 (+100.0%) | 13.6K +13.6K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD17.80 +0.0% | 8 qtrs — |
| 81 | EVERSOURCE WEALTH ADVISORS, LLC | 661.00 -64.0 (-8.8%) | 11.8K +8.9K (+303.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.45 +626.5% | 4 qtrs — |
| 82 | FORTITUDE FAMILY OFFICE, LLC | 511.00 +— (+0.0%) | 9.1K +7.0K (+342.8%) | 0.00% +0.000 pp | 0.00% +0.002 pp | USD2.98 +497.3% | 3 qtrs — |
| 83 | NISA INVESTMENT ADVISORS, LLC | 338.00 +— (+0.0%) | 6.0K +4.7K (+342.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.17 +720.3% | 6 qtrs — |
| 84 | RUSSELL INVESTMENTS GROUP, LTD. | 306.00 +— (+0.0%) | 5.4K +4.2K (+342.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.20 +709.1% | 5 qtrs — |
| 85 | NORTH STAR INVESTMENT MANAGEMENT CORP. | 174.00 +— (+0.0%) | 3.1K +2.4K (+343.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.02 +342.8% | 2 qtrs — |
| 86 | CWM, LLC | 154.00 -770.0 (-83.3%) | 3.0K -1.0K (-25.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD2.49 +614.9% | 6 qtrs — |
| 87 | GLOBAL RETIREMENT PARTNERS, LLC | 150.00 +150.0 (+100.0%) | 2.7K +2.7K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 88 | JPMORGAN CHASE & CO | 146.00 +146.0 (+100.0%) | 2.6K +2.6K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD17.79 +0.1% | 1 qtrs NEW |
| 89 | US BANCORP \DE\ | 113.00 +113.0 (+100.0%) | 2.0K +2.0K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD17.80 +0.0% | 1 qtrs NEW |
| 90 | ROYAL BANK OF CANADA | 34.00 -161.0 (-82.6%) | 1.0K +— (+0.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD2.79 +538.0% | 7 qtrs — |
| 91 | JONES FINANCIAL COMPANIES LLLP | 33.00 +33.0 (+100.0%) | 587.00 +587.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD17.79 +0.1% | 1 qtrs NEW |
| 92 | FARTHER FINANCE ADVISORS, LLC | 31.00 +31.0 (+100.0%) | 552.00 +552.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD17.77 +0.2% | 1 qtrs NEW |
| 93 | OPTIVER HOLDING B.V. | 20.00 +— (+0.0%) | 356.00 +276.0 (+345.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.00 +345.0% | 2 qtrs — |
| 94 | SBI SECURITIES CO., LTD. | 12.00 +9.0 (+300.0%) | 214.00 +202.0 (+1,683.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD14.00 +27.1% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 58 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.16% | 5.49M | 0.35% |
| 2 | Virtus Biotech Clinical Trials ETF BBC | 0.76% | 436.9K | 0.65% |
| 3 | ALPS Medical Breakthroughs ETF SBIO | 0.48% | 1.01M | 0.50% |
| 4 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.24% | 56.4K | 1.22% |
| 5 | iShares Micro-Cap ETF IWC | 0.16% | 2.33M | 0.60% |
| 6 | Innovator U.S. Small Cap Managed Floor ETF RFLR | 0.09% | 81.1K | 0.89% |
| 7 | iShares Biotechnology ETF IBB | 0.06% | 5.98M | 0.44% |
| 8 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.05% | 483.4K | 0.20% |
| 9 | iShares Russell 2000 Growth ETF IWO | 0.04% | 6.38M | 0.24% |
| 10 | State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc) R2US.L | 0.02% | 1.35M | 0.30% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
4.00
Bullish
Ratio by volume
3.00
Bullish
Buys
8
Sells
2
Shares acquired
781.5K
Shares disposed
9.0K
Cash buys
—
Cash sales
—
Net activity
+772,433
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-01 | Smith Nicholas Conrad | Officer | F-InKind | D | Common Stock | 2,806 | 19.69 | 55.3K | 24,060 | D | ↗ |
| 2026-03-01 | Etkin Amit | Director / Officer | F-InKind | D | Common Stock | 6,227 | 19.69 | 122.6K | 1,233,949 | D | ↗ |
| 2026-02-11 | Smith Nicholas Conrad | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 200,000 | 16.71 | 3.34M | 200,000 | D | ↗ |
| 2026-02-11 | Savitz Adam | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 124,000 | 16.71 | 2.07M | 124,000 | D | ↗ |
| 2026-02-11 | Hanley Jr. Michael Conick | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 131,000 | 16.71 | 2.19M | 131,000 | D | ↗ |
| 2026-02-11 | Etkin Amit | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 306,000 | 16.71 | 5.11M | 306,000 | D | ↗ |
| 2026-01-02 | York Gwill | Director | A-Award | A | Stock Option (right to buy) | 5,243 | 16.59 | 87.0K | 5,243 | D | ↗ |
| 2026-01-02 | Sanchez Ramiro | Director | A-Award | A | Stock Option (right to buy) | 3,806 | 16.59 | 63.1K | 3,806 | D | ↗ |
| 2026-01-02 | Manji Husseini | Director | A-Award | A | Employee Stock Option (right to buy) | 4,228 | 16.59 | 70.1K | 4,228 | D | ↗ |
| 2026-01-02 | Cox Christopher Nixon | Director | A-Award | A | Stock Option (right to buy) | 7,189 | 16.59 | 119.3K | 7,189 | D | ↗ |
| 2025-08-12 | Sanchez Ramiro | Director | A-Award | A | Stock Option (right to buy) | 30,574 | 3.18 | 97.2K | 30,574 | D | ↗ |
| 2025-07-03 | Smith Nicholas Conrad | Officer | D-Return | D | Employee Stock Option (Right to Buy) | 135,000 | 4.20 | 567.0K | 0 | D | ↗ |
| 2025-07-03 | Savitz Adam | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 76,000 | 2.35 | 178.6K | 76,000 | D | ↗ |
| 2025-07-03 | Hanley Jr. Michael Conick | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 188,000 | 2.35 | 441.8K | 188,000 | D | ↗ |
| 2025-07-03 | Etkin Amit | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 247,290 | 2.35 | 581.1K | 247,290 | D | ↗ |
| 2025-05-13 | York Gwill | Director | A-Award | A | Stock Option (right to buy) | 15,287 | 2.37 | 36.2K | 15,287 | D | ↗ |
| 2025-05-13 | Manji Husseini | Director | A-Award | A | Stock Option (right to buy) | 15,287 | 2.37 | 36.2K | 15,287 | D | ↗ |
| 2025-05-13 | Dreyfus Andrew | Director | A-Award | A | Stock Option (right to buy) | 15,287 | 2.37 | 36.2K | 15,287 | D | ↗ |
| 2025-05-13 | Cox Christopher Nixon | Director | A-Award | A | Stock Option (right to buy) | 15,287 | 2.37 | 36.2K | 15,287 | D | ↗ |
| 2025-02-05 | Smith Nicholas Conrad | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 135,000 | 4.20 | 567.0K | 135,000 | D | ↗ |
| 2025-02-05 | Savitz Adam | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 76,000 | 4.20 | 319.2K | 76,000 | D | ↗ |
| 2025-02-05 | Hanley Jr. Michael Conick | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 4.20 | 525.0K | 125,000 | D | ↗ |
| 2025-02-05 | Etkin Amit | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 215,000 | 4.20 | 903.0K | 215,000 | D | ↗ |
| 2025-01-02 | York Gwill | Director | A-Award | A | Stock Option (right to buy) | 19,558 | 4.38 | 85.7K | 19,558 | D | ↗ |
| 2025-01-02 | Manji Husseini | Director | A-Award | A | Stock Option (right to buy) | 14,195 | 4.38 | 62.2K | 14,195 | D | ↗ |
| 2025-01-02 | Cox Christopher Nixon | Director | A-Award | A | Stock Option (right to buy) | 25,236 | 4.38 | 110.5K | 25,236 | D | ↗ |
| 2024-07-10 | Savitz Adam | Officer | P-Purchase | A | Common Stock | 2,931 | 13.22 | 38.7K | 39,851 | — | ↗ |
| 2024-07-09 | Savitz Adam | Officer | P-Purchase | A | Common Stock | 1,388 | 13.15 | 18.3K | 36,920 | — | ↗ |
Executive team
Top executives
Shares Outstanding
31.95M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Amit Etkin, M.D., Ph.D. President, Chief Executive Officer, and Chair of the Board | 650.7K | 220.0K | — | 934.2K | 358.1K | 25.6K | 2.19M | 42.69% | ↗ |
| 2 | 2025 | Nicholas Smith Chief Financial Officer and Chief Business Officer | 493.7K | 220.0K | — | 594.7K | 222.3K | 10.8K | 1.54M | 38.58% | ↗ |
| 3 | 2025 | Michael Hanley Chief Operating Officer | 488.8K | — | — | 517.6K | 195.5K | 11.0K | 1.21M | 42.67% | ↗ |
| 4 | 2024 | Amit Etkin, M.D., Ph.D. President, Chief Executive Officer, and Chair of the Board | 603.1K | — | 516.5K | 2.55M | 368.4K | 24.5K | 4.07M | 75.50% | ↗ |
| 5 | 2024 | Michael Hanley Chief Operating Officer | 283.2K | — | — | 1.88M | 201.2K | 82.0K | 2.44M | 76.81% | ↗ |
| 6 | 2024 | Nicholas Smith Chief Financial Officer and Chief Business Officer | 466.5K | — | 285.0K | 1.03M | 203.3K | 10.7K | 2.00M | 65.91% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Amit Etkin | Founder, Chairman of the Board, Chief Executive Officer & President | 1M | — |
| Nicholas C. Smith | Chief Financial Officer & Chief Business Officer | 946.9K | male |
| Michael C. Hanley | Chief Operating Officer | 695.3K | male |
| Adam Savitz | Chief Medical Officer | 579.6K | male |
| Erin R. McQuade | General Counsel, Chief Administrative Officer & Corporate Secretary | — | female |
| Dan Segal | Co-Founder & Strategic Advisor | — | male |
| Jessica Powell | Chief Development Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ANRO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
